Posted in | News | Materials Processing

$5m Grant for Microchannel Reactors for Biofuel Production

Microchannel reactors provide the key to intensifying the Fischer-Tropsch (FT) reaction, opening up the possibility of economical and environmentally friendly distributed production of third generation transportation biofuels. A $5 million grant awarded to Velocys Inc, a subsidiary of the Oxford Catalysts Group, from the Ohio-based Third Frontier Research Commercialization Program will help to bring the advantages of microchannel reactors to alternative fuel production facilities to make it possible to convert small quantities of FT materials to meet diesel and jet fuel specifications. The grant is part of the $1.6 billion, 10-year Third Frontier Program initiative designed to support the development of a world-class research capacity in Ohio.

In the grant-funded research, Velocys will apply its microchannel technology to intensify the hydrocracking of heavy waxes produced via FT for the production of diesel fuels. Successful extension of the microchannel technology platform will result in modular, less capital-intensive hydrocracking units. These, in turn, will improve plant economics. It will also help to maximise the production of transportation fuels from the heavy waxes produced via FT in biomass to liquid (BTL) and gas to liquid (GTL) plants.

Tom Hickey, Velocys president and managing director said: "Economic hydrocracking of FT waxes is an essential element of an integrated biomass-to-liquids facility. Velocys microchannel technology greatly improves this process step and will speed the development of third generation biofuels."

Roy Lipski, CEO of Oxford Catalysts Group said: "The world is beginning to depend on alternative fuels. These FT fuels must be substantially upgraded before they can be used as transportation fuels. Velocys hydroprocessing technology will allow this to be done economically and in a distributed manner."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.